Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers

References

• CoultasLChawengsaksophakKRossantJEndothelial cells and VEGF in vascular developmentNature200543893794516355211
   PubMed Web of Science ®Google Scholar
• WertherKChristensenIJBrünnerNNielsenHJSoluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study GroupEur J Surg Oncol20002665766211078612
   PubMed Web of Science ®Google Scholar
• SeoYBabaHFukudaTHigh expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinomaCancer2000882239224510820344
   PubMed Web of Science ®Google Scholar
• IkedaNAdachiMTakiTPrognostic significance of angiogenesis in human pancreatic cancerBr J Cancer1999791553156310188906
   PubMed Web of Science ®Google Scholar
• ClaudioPPRussoGKumarCApRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significanceClin Cancer Res2004103509351715161709
   PubMed Web of Science ®Google Scholar
• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med1971285118211864938153
   PubMed Web of Science ®Google Scholar
• FolkmanJKlagsbrunMAngiogenic factorsScience19872354424472432664
   PubMed Web of Science ®Google Scholar
• FolkmanJWhat is the evidence that tumors are angiogenesis dependent?J Natl Cancer Inst199082461688381
   PubMed Web of Science ®Google Scholar
• AugustinHGTranslating angiogenesis research into the clinic: the challenges aheadBr J Radiol2003761S3S1015456709
   PubMed Web of Science ®Google Scholar
• RheeJHoffPMAngiogenesis inhibitors in the treatment of cancerExpert Opin Pharmacother200561701171116086656
   PubMed Web of Science ®Google Scholar
• FerraraNAlitaloKClinical applications of angiogenic growth factors and their inhibitorsNat Med199951359136410581076
   PubMed Web of Science ®Google Scholar
• IgnoffoRJOverview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factorAm J Health Syst Pharm20046121 Suppl 5S21S2615552623
   PubMed Web of Science ®Google Scholar
• ChaseJLClinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancerPharmacotherapy20082811 Pt 223S30S18980549
   PubMed Web of Science ®Google Scholar
• KimKJLiBHouckKThe vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodiesGrowth Factors1992753641380254
   PubMed Web of Science ®Google Scholar
• http://www.fda.gov/bbs/topics/NEWS/2004/NEW01027.html.
   Google Scholar
• http://www.fda.gov/bbs/topics/NEWS/2006/NEW01488.html.
   Google Scholar
• http://www.fda.gov/cder/Offices/OODP/whatsnew/bevacizumab200802.html.
   Google Scholar
• de GramontAVan CutsemEInvestigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancerOncology200569Suppl 3465616301835
   PubMed Web of Science ®Google Scholar
• BurrisH3rdRocha-LimaCNew therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathwaysOncologist20081328929818378539
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardECancer statisticsCA Cancer J Clin200858719618287387
   PubMed Web of Science ®Google Scholar
• GoldbergRMSargentDJMortonRFA randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancerJ Clin Oncol200422233014665611
   PubMed Web of Science ®Google Scholar
• CassidyJTaberneroJTwelvesCXELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJ Clin Oncol2004222084209115169795
   PubMed Web of Science ®Google Scholar
• SaltzLBCoxJVBlankeCIrinotecan plus fluorouracil and leucovorin for metastatic colorectal cancerN Engl J Med200034390591411006366
   PubMed Web of Science ®Google Scholar
• TournigandCAndreTAchilleEFOLFIRI followed by FOLFOX or the recer sequence in advanced colorectal cancer: a randomized GERCOR studyJ Clin Oncol20042222923714657227
   PubMed Web of Science ®Google Scholar
• ColucciGGebbiaVPaolettiGPhase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Grouppo Oncologico Dell’Italia MeridionaleJ Clin Oncol2005234866487515939922
   PubMed Web of Science ®Google Scholar
• KabbinavarFHurwitzHIFehrenbacherLPhase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerJ Clin Oncol200321606512506171
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLHainsworthJDBevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancerJ Clin Oncol2005233502350815908660
   PubMed Web of Science ®Google Scholar
• KabbinavarFFSchulzJMcCleodMAddition of bevacizumab to bolus fluorouracil and leucovorin in first line metastatic colorectal cancer: results of a randomized phase II trialJ Clin Oncol2005233697370515738537
   PubMed Web of Science ®Google Scholar
• KabbinavarFFHambletonJMassRDCombination analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerJ Clin Oncol20052337053712
   Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• FuchsCSMarshallJMitchellERandomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C StudyJ Clin Oncol2007254779478617947725
   PubMed Web of Science ®Google Scholar
• FuchsCSMarshallJBarruecoJRandomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C studyJ Clin Oncol20082668969018235136
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDíaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol2008262013201918421054
   PubMed Web of Science ®Google Scholar
• HochsterHHartLLRamanathanRKSafety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE studyJ Clin Oncol20082635233529 Erratum in: J Clin Oncol. 2008;26:469718640933
   PubMed Web of Science ®Google Scholar
• HochsterHSGrotheyAShpilskyAEffect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial2008 Gastrointestinal Cancers Symposium Abstract 280
   Google Scholar
• GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol2007251539154417442997
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaSCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med200435133734515269313
   PubMed Web of Science ®Google Scholar
• SaltzLBLenzHJKindlerHLRandomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 studyJ Clin Oncol2007254557456117876013
   PubMed Web of Science ®Google Scholar
• HechtJRMitchellEChidiacTAn updated analysis of the safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) ± panitumumab (pmab) for firstline treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). [abstract]Program and abstracts of the 2008 Gastrointestinal Cancers SymposiumOrlando, FLJanuary 25–27, 2008
   Google Scholar
• HechtJRMitchellEChidiacTInterim results from PACCE: Irinotecan (iri)/bevacizumab (bev) ± panitumumab as first-line treatment for metastatic colorectal cancer. [abstract]Proceedings and abstracts of the 2008 Gastrointestinal Cancers SymposiumOrlando, FLJanuary 25–27, 2008
   Google Scholar
• TolJKoopmanMRodenburgCJA randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicityAnn Oncol20081973473818272912
   PubMed Web of Science ®Google Scholar
• TolJKoopmanMCatsAChemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancerN Engl J Med200936056357219196673
   PubMed Web of Science ®Google Scholar
• Combination chemotherapy and bevacizumab with or without erlotinib in treating patients with metastatic colorectal cancer that cannot be removed by surgery www.clinicaltrials.gov. ClinicalTrials.gov identifier: NCT00265824
   Google Scholar
• Irinotecan and Cetuximab with or without bevacizumab in treating patients with metastatic colorectal cancer that progressed during first-line therapy http://clinicaltrials.gov/ct2/show/NCT00499369
   Google Scholar
• MeyerhardtJAStuartKFuchsCSPhase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancerAnn Oncol2007181185118917483115
   PubMed Web of Science ®Google Scholar
• AllegraCJYothersGO’ConnellMJInitial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. 2008 ASCO annual meetingJ Clin Oncol200826May 20 Suppl; abstr 4006
   Google Scholar
• WolmarkNYothersGO’ConnellMJA phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08J Clin Oncol20092718s(suppl; abstr LBA4)
   Google Scholar
• JemalASiegelRWardECancer statistics, 2009CA Cancer J Clin20095922524919474385
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol199715240324139196156
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol2007251960196617452677
   PubMed Web of Science ®Google Scholar
• KindlerHLFribergGSinghDAPhase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancerJ Clin Oncol2005238033804016258101
   PubMed Web of Science ®Google Scholar
• KimGPObergAKabatBNCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. [abstract]J Clin Oncol2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Suppl):4113
   Google Scholar
• KimGPObergALFosterNRPhase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. [abstract]J Clin Oncol2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Suppl):4553
   Google Scholar
• LouvetCLabiancaRHammelPGemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trialJ Clin Oncol2005233509351615908661
   PubMed Web of Science ®Google Scholar
• HeinemannVQuietzschDGieselerFRandomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancerJ Clin Oncol2006243946395216921047
   PubMed Web of Science ®Google Scholar
• HeinemannVLabiancaRHinkeALouvetCIncreased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter studyAnn Oncol2007181652165917660491
   PubMed Web of Science ®Google Scholar
• HeinemannVBoeckSHinkeALabiancaRLouvetCMeta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer200888218373843
   PubMed Web of Science ®Google Scholar
• AstsaturovNJMeropolNJAlpaughRKA randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. [abstract]J Clin Oncol2007 ASCO Annual Meeting Proceedings. Part I. Vol. 25, No. 18S (June 20 Suppl):4556
   Google Scholar
• KindlerHLGangadharTKarrisonTFinal analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC). [abstract]J Clin Oncol2008 ASCO Annual Meeting Proceedings:Abstract 4502
   Web of Science ®Google Scholar
• KindlerHLNiedzwieckiDHollisDA double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB)J Clin Oncol20072518s(Suppl) Abstract 4508
   Google Scholar
• Van CutsemEVervenneWLBennounaJPhase III Trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancerJ Clin Oncol2009272231223719307500
   PubMed Web of Science ®Google Scholar
• YamanakaYFriessHKobrinMSCoexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressivenessAnticancer Res1993135655698317885
   PubMed Web of Science ®Google Scholar
• LongoRCacciamaniFNasoGPancreatic cancer: From molecular signature to target therapyCrit Rev Oncol Hematol20086819721118436450
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med200835937839018650514
   PubMed Web of Science ®Google Scholar
• FinnRSBentleyGBrittenCDAmadoRBusuttilRWTargeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse modelLiver Int20092928429018482274
   PubMed Web of Science ®Google Scholar
• SiegelABCohenEIOceanAPhase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinomaJ Clin Oncol2008262992299818565886
   PubMed Web of Science ®Google Scholar
• ZhuAXBlaszkowskyLSRyanDPPhase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinomaJ Clin Oncol2006241898190316622265
   PubMed Web of Science ®Google Scholar
• ZhuAXHolalkereNSMuzikanskyAHorganKSahaniDVEarly antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinomaOncologist20081312012518305056
   PubMed Web of Science ®Google Scholar
• ThomasMBMorrisJSChadhaRPhase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinomaJ Clin Oncol20092784385019139433
   PubMed Web of Science ®Google Scholar
• KasebAOIwasakiMJavleMBiological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC)J Clin Oncol20092715s Suppl Abstract 4522
   Google Scholar
• OngLCSongICJinYEffective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic modelMol Imaging Biol20091133434219330383
   PubMed Web of Science ®Google Scholar
• Antiangiogenic treatment of HCC with bevacizumab and Rad001 http://www.clinicaltrials.gov/ct2/show/NCT00775073
   Google Scholar
• TaiCJChiouHYWuCHPanSLiuJDRapid resolution of liver metastasis from cholangiocarcinoma after bevacizumab with cisplatin and high-dose fluorouracil plus leucovorinOnkologie20062917918016601375
   PubMedGoogle Scholar
• HolenKDMahoneyMRLoConteNKEfficacy report of a multicenter phase II trial testing a biologic-only combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer (BC): A Phase II Consortium (P2C) studyJ Clin Oncol200826Meeting Abstracts Abstract 4522
   Google Scholar
• ErogluADemirciSAyyildizASerum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancerBr J Cancer1999801630163410408410
   PubMed Web of Science ®Google Scholar
• KarayiannakisASyrigosKNPolychronidisACirculating VEGF levels in the serum of gastric cancer patientsAnn Surg2002236374212131083
   PubMed Web of Science ®Google Scholar
• NinomiyaSInomataMTajimaMEffect of Bevacizumab, a Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, on Peritoneal Metastasis of MNK-45P Human Gastric Cancer in MiceJ Surg Res200915419620219329124
   PubMed Web of Science ®Google Scholar
• ShahMARamanathanRKIlsonDHMulticenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaJ Clin Oncol2006245201520617114652
   PubMed Web of Science ®Google Scholar
• KelsenDJhawerMIlsonDAnalysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trialJ Clin Oncol20092715s Suppl Abstract 4512
   Google Scholar
• El-RayesBFPatelBZalupskiMA phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancerJ Clin Oncol20092715s Suppl Abstract 4563
   Google Scholar
• YaoJCNgCHoffPMImproved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumabJ Clin Oncol2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Suppl):Abstract 4007
   Web of Science ®Google Scholar
• KunzPLKuoTKaiserHLA phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary resultsJ Clin Oncol200826May 20 Suppl Abstract 15502
   Google Scholar
• KulkeMHStuartKEarleCCA phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumorsJ Clin Oncol2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Suppl):Abstract 4044
   Google Scholar
• ArnoldRMüllerHSchade-BrittingerCPlacebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study groupJ Clin Oncol20092715s Suppl Abstract 4508
   Google Scholar